Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting

Bolt Biotherapeutics (BOLT) announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology Annual Meeting. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate in development for the treatment of patients with HER2-expressing cancer. The ASCO presentation will include comprehensive results from the company’s Phase 1 single-agent and combination dose-escalation trial of BDC-1001 that enrolled more than 100 patients. "We look forward to presenting a comprehensive data set at ASCO that provides detailed safety, efficacy, pharmacokinetic and pharmacodynamic results from our recently completed Phase 1 dose-escalation trial evaluating BDC-1001 as a single agent and in combination with nivolumab," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "These data support the recommended Phase 2 dose and schedule for BDC-1001. We are making steady progress towards initiating two Phase 2 studies in 2023 evaluating BDC-1001 in multiple single-agent solid tumor settings, and in combination with nivolumab supplied by our partner BMS and with pertuzumab supplied by our partner Roche (RHHBY)."